Spectral Platforms

Founded in 2011 and headquartered in Monrovia, California, Spectral Platforms is dedicated to revolutionizing the rapid diagnosis of infectious diseases. The company's mission is to significantly reduce the time required to detect pathogens and determine antimicrobial susceptibility, thereby improving patient outcomes and combating antibiotic resistance. Spectral Platforms offers innovative diagnostic tools such as InSpector, which detects pathogenic microorganisms, and BloodFAST, which characterizes pathogens and their antimicrobial susceptibility directly from blood samples without the need for culture steps.

Spectral Platforms has attracted notable investors and industry experts who support its groundbreaking technology. The company's achievements include developing diagnostic tools that can identify pathogens in just 5 minutes and determine antimicrobial resistance in 40 minutes, compared to traditional methods that take much longer. These advancements have the potential to transform clinical diagnostics, offering faster and more accurate treatment decisions, ultimately impacting public health positively by reducing the spread of infectious diseases and improving antibiotic stewardship.